ArticleEpilepsia2026
Long-term prognosis of pharmacotherapy in newly diagnosed focal epilepsy patients and the predictive value of baseline seizure timing: A prospective cohort study.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveEpilepsy is a highly heterogeneous neurological disorder with significant prognostic variability. Accurate long-term outcome prediction remains a clinical challenge. We investigated pharmacotherapeutic prognosis and key predictors, particularly baseline seizure timing, to guide individualized treatment.
methodsThis prospective cohort study consecutively enrolled newly diagnosed focal epilepsy patients from the epilepsy specialist clinic of the Department of Neurology in our hospital between September 2015 and September 2025. We applied the Cox proportional hazards regression model to analyze the association between baseline factors and prognosis to identify independent predictors.
resultsA total of 563 patients with ≥36-month follow-up (median = 48.0 months, interquartile range [IQR] = 36.0-78.0) were analyzed. Among them, 64.8% (365/563) achieved seizure freedom at least once (median = 27.0 months, 95% confidence interval [CI] = 22.5-31.5), and 35.9% (131/365) relapsed after seizure freedom; 25.4% (143/563) developed drug resistance, with 6.3% (9/143) later converting to drug-responsive status. At the end of follow-up, 50.8% (286/563) were classified as drug-responsive, 23.8% (134/563) as having drug-resistant epilepsy (DRE), and 25.4% (143/563) as having an undetermined prognosis. Among patients with drug-responsive epilepsy, 63.6% (182/286) achieved seizure freedom with monotherapy. Multivariate analysis identified baseline wake-related seizures (hazard ratio [HR] = 1.743, 95% CI = 1.101-2.760, p = .018), cluster seizures (HR = 2.630, 95% CI = 1.845-3.749, p < .001), status epilepticus (HR = 2.126, 95% CI = 1.394-3.242, p < .001), and sleep problems (HR = 1.740, 95% CI = 1.178-2.572, p = .005) as independent DRE risk factors. SIGNIFICANCE: This prospective large-sample study revealed the inherent complexity and dynamic nature of prognostic assessment in patients with newly diagnosed focal epilepsy. We identified independent prognostic predictors for this condition, first confirming baseline wake-related seizures as a predictor of poor prognosis to guide early risk stratification and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.